Hjem › Blærekreft › Colorado
Kliniske studier for Blærekreft i Colorado
20 studier for Blærekreft søker deltakere på steder i Colorado.
Byer i Colorado
- Denver11 studier
- Aurora9 studier
- Highlands Ranch7 studier
- Centennial7 studier
- Lakewood4 studier
- Greeley4 studier
- Loveland4 studier
- Fort Collins4 studier
Offisiell studietekst (engelsk)
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Sarah Cannon Research Institute at HealthOne, Denver
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT06465069Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Rocky Mountain Regional VA Medical Center, Aurora
- UCHealth University of Colorado Hospital, Aurora
- Penrose-Saint Francis Healthcare, Colorado Springs
- og 15 flere
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
Alder 40 til 75 · Alle kjønn · Oppdatert 2. okt. 2026 · NCT05334069Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
- Shaw Cancer Center, Edwards
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT06770582A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
- Urology Associates ( Site 0144), Littleton
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT06833073Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
- UCHealth University of Colorado Hospital, Aurora
- UCHealth - Cherry Creek, Denver
- Shaw Cancer Center, Edwards
- og 6 flere
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT07061964Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
- Rocky Mountain Cancer Center, Aurora
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 30. sep. 2026 · NCT07566156Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
- Rocky Mountain Cancer Centers, LLP, Aurora
- Rocky Mountain Cancer Centers, LLP, Denver
- Rocky Mountain Cancer Centers, LLP, Lone Tree
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 28. sep. 2026 · NCT07421700DESTINY-PANTUMOUR04
- Research Site, Boulder
RekruttererObservasjonsstudie
Alder 18 til 130 · Alle kjønn · Oppdatert 25. sep. 2026 · NCT07124000A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
- AdventHealth Medical Group - Porter, Denver
- Colorado West Healthcare System - Grand Valley Oncology, Grand Junction
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT07218380ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- University of Colorado, Aurora
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 14. sep. 2026 · NCT05059444Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
- Colorado Urology, Lakewood
- Urology Associates, Lone Tree, Lone Tree
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 3. sep. 2026 · NCT06567743The Vanguard Study: Testing a New Way to Screen for Cancer
- Keefe Memorial Hospital, Cheyenne Wells
- Kaiser Permanente-Franklin, Denver
- Poudre Valley Hospital, Fort Collins
- og 5 flere
RekruttererFrivillige helsepersonell ønskes velkommen
Alder 45 til 75 · Alle kjønn · Oppdatert 2. sep. 2026 · NCT06995898Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
- Colorado University - Anshutz, Aurora
- AdventHealth Medical Group Urology of Denver, Denver
- Advanced Urology, Lakewood
- og 1 flere
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 24. aug. 2026 · NCT05951179Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
- UCHealth University of Colorado Hospital, Aurora
- UCHealth - Cherry Creek, Denver
- UCHealth Highlands Ranch Hospital, Highlands Ranch
- og 1 flere
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 18. aug. 2026 · NCT07097142LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
- Colorado Clinical Research, Lakewood
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 7. aug. 2026 · NCT04752722Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
- Rocky Mountain Cancer Centers, LLP, Denver
- Shaw Cancer Center, Edwards
RekruttererFase 2/3
Alder 18 og eldre · Alle kjønn · Oppdatert 29. jul. 2026 · NCT07106762Integrated Cancer Repository for Cancer Research
- Advent Health, Greenwood Village
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
Alder 19 til 110 · Alle kjønn · Oppdatert 29. jun. 2026 · NCT02012699Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
- Sarah Cannon Research Institute at HealthONE, Denver
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 18. feb. 2026 · NCT07030257Improving Care for Rural Patients With Solid Tumors
- University of Colorado Hospital, Aurora
- Memorial Hospital Central, Colorado Springs
- Memorial Hospital North, Colorado Springs
- og 10 flere
Rekrutterer
Alder 18 til 99 · Alle kjønn · Oppdatert 5. feb. 2026 · NCT04916990SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Aurora
- Massive Bio SYNERGY-AI site, Denver
- Massive Bio SYNERGY-AI site, Littleton
RekruttererObservasjonsstudie
Alle aldre · Alle kjønn · Oppdatert 28. okt. 2025 · NCT03452774Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.